The effects of the proliferator-activated receptor gamma (PPARy) peroxisome agonist rosiglitazone on airway hyperreactivity.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2011
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2011 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.
- 01 Sep 2011 Primary endpoint identified as Methacholine provocation concentration as reported by ClinicalTrials.gov.